RSS0343 Tabella
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adolescent Asthma
Conditions
Adolescent Asthma
Trial Timeline
Jan 22, 2025 → Dec 1, 2027
NCT ID
NCT06775340About RSS0343 Tabella
RSS0343 Tabella is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Adolescent Asthma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06775340. Target conditions include Adolescent Asthma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06775340 | Phase 2 | Recruiting |
Competing Products
8 competing products in Adolescent Asthma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lorcaserin | Eisai | Phase 1 | 33 |
| Exenatide Once Weekly + Placebo | AstraZeneca | Phase 3 | 77 |
| Placebo + IBI362 | Innovent Biologics | Phase 3 | 76 |
| IBI362 + IBI362 placebo | Innovent Biologics | Phase 1 | 32 |
| Antipsychotics, mood stabilizers, etc. | Brain Biotech | Pre-clinical | 15 |
| voclosporin | Aurinia Pharmaceuticals | Phase 3 | 72 |
| Voclosporin + Placebo Oral Capsule | Aurinia Pharmaceuticals | Phase 3 | 72 |
| rizatriptan benzoate | Organon | Phase 3 | 72 |